Special Issue

Mechanisms and Therapeutic Strategies of Brain and Spinal Cord Injury

Message from the Guest Editors

Brain and spinal cord injuries are devastating conditions that can lead to serious long-term disability or even death. Understanding the mechanisms behind these injuries and developing effective therapeutic strategies is crucial to improving outcomes for affected individuals. These injuries involve complex primary and secondary injury mechanisms that require multifaceted therapeutic strategies. Advances in surgical techniques, pharmacotherapy, rehabilitation, and experimental treatments hold promise for improving the quality of life of those affected. Ongoing research into innovative therapies such as neuroprotectants, stem cells, gene therapy, invasive and non-invasive neuromodulation techniques, and biomaterials continues to provide hope for more effective treatments in the future.

Guest Editors

Dr. Hatice Kumru Institut Guttmann, Badalona, Spain

Dr. Xabier Urra

Department of Neurology, Hospital Clínic, Barcelona, Spain

Deadline for manuscript submissions

31 May 2026



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/214790

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).